Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylaspartic Acid SCHEMBL31119891 | 1.00 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL37946 | 1.00 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL163861 | 1.00 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL28602698 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL27883016 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL27980402 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL27980404 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL27908998 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL28715832 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL27908423 | 0.98 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066314-B | Process of preparation of optically active alpha aminoacetals | CLARIANT SPECIALTY FINE CHEM | 2014-07-30 | — | — | CN | claimed |
| CN-1434795-B | Acylated Pseudodipeptides with Functionalized Auxiliary Branches | OM PHARMA | 2012-11-14 | — | — | CN | claimed |
| EP-2183201-B1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | ESTEVE QUIMICA SA (ES) | 2012-03-28 | — | — | EP | claimed |
| US-7968712-B2 | Process for the resolution of zopiclone and intermediate compounds | ESTEVE QUIMICA, S.A. (ES) | 2011-06-28 | — | — | US | claimed |
| CN-102066314-A | Process of preparation of optically active alpha aminoacetals | CLARIANT SPECIALTY FINE CHEM | 2011-05-18 | — | — | CN | claimed |
| US-20100274018-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | ESTEVE QUIMICA, S.A. (ES) | 2010-10-28 | — | — | US | claimed |
| US-7772396-B2 | Process for the resolution of zopiclone and intermediate compounds | Esteve Quimica, S.A. Avda. Mare de deu de Monsterrat (ES) | 2010-08-10 | — | — | US | claimed |
| CN-101772475-A | Method and intermediate compounds for resolving zopiclone | ESTEVE QUIMICA SA | 2010-07-07 | — | — | CN | claimed |
| EP-2183201-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | Esteve Química, S.A. (ES) | 2010-05-12 | — | — | EP | claimed |
| WO-2009016251-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | Esteve Química, S.A. (ES) | 2009-02-05 | — | — | WO | claimed |
| US-20090036681-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | ESTEVE QUIMICA, S.A. (ES) | 2009-02-05 | — | — | US | claimed |
| EP-2020403-A1 | Process for the resolution of zopiclone and intermediate compounds | ESTEVE QUIMICA, S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| CN-1874992-A | Resolution of 3-amino alkylnitriles | PFIZER (US) | 2006-12-06 | — | — | CN | claimed |
| WO-2025006958-A2 | METHODS OF TREATING AMYLOIDOSIS OF THE SKIN AND REJUVENATING SKIN USING BIOSENSORS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-118369325-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2009016251-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | Esteve Química, S.A. (ES) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036681-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | ESTEVE QUIMICA, S.A. (ES) | 2009-02-05 | — | — | US | disclosed |
| EP-2020403-A1 | Process for the resolution of zopiclone and intermediate compounds | ESTEVE QUIMICA, S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
| CN-1874992-A | Resolution of 3-amino alkylnitriles | PFIZER (US) | 2006-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274018-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | CYP3A5, ZP1, AZI2 | MAPT 2951/4885KDM4E 1637/4885THRB 3477/4885 |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | MAPT 2759/4885KDM4E 4705/4885THRB 1875/4885 |
| US-20090036681-A1 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS | CYP3A5, ZP1, AZI2 | MAPT 2951/4885KDM4E 1637/4885THRB 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.